Lactoferrin in Covid-19 Hospitalized Patients (LAC)
Covid19
About this trial
This is an interventional treatment trial for Covid19
Eligibility Criteria
Inclusion Criteria:
- Hospitalization in non-ICU ward for Covid-19 infection, with virological diagnosis SARS-CoV2 confirmed via RT-PCR (or quick test)
- Age>18 aa
- Covid symptomatology story from no more than 12 days
Exclusion Criteria:
- Refusal of consent
- Need for immediate admission to intensive care
- Severe neoplasms (in advanced stage)
- Allergies or intolerances known to Lactoferrin
4. Already being treated with Lactoferrin at the entrance to the Hospital 5. Patients with end-stage renal failure (stage 5) 6. Extremely serious general conditions to suggest an imminent exitus 7. Clinical conditions of absolute impossibility of tolerating ingestion of drugs/capsules due to conditions contraining the initiation of therapy for os.
Sites / Locations
- ASL BI Ospedale degli InfermiRecruiting
- AOU Ospedale Maggiore della CaritàRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Group A
Group B
Standard Anti-Covid-19 Therapy + Oral Administration of Bovine Lactoferrin 400mg (two capsules of Mosiac 200 product) every 12 h (i.e., fixed dose 800 mg / day) for 30 days and still away from meals
Standard anti-Covid-19 therapy + Placebo administration (capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.